The efficacy of hydrogen/oxygen therapy favored the recovery of omicron SARS-CoV-2 variant infection : results of a multicenter, randomized, controlled trial
Copyright © 2023 JCBN..
Clinical studies had found that hydrogen/oxygen mixed inhalation was beneficial to ameliorate the respiratory symptoms in the adjuvant treatment of patients with COVID-19. We aimed to explore the efficacy of hydrogen/oxygen therapy in favoring the recovery of Omicron SARS-CoV-2 variant infection. There were 64 patients who randomly assigned to receive hydrogen/oxygen inhalation (32 patients) and oxygen inhalation (32 patients). The average shedding duration of Omicron in hydrogen/oxygen group was shorter than oxygen group. The trend of cumulative negative conversion rate of Omicron increased gradually after the third day. The IL-6 levels in hydrogen/oxygen group decreased by 22.8% compared with the baseline. After hydrogen/oxygen mixed gas inhalation, the lymphocyte count increased to 61.1% of the baseline on the 3rd day in the hydrogen/oxygen group. More patients in the hydrogen/oxygen group had resolution of pulmonary lesions. Our study showed the beneficial trends of molecular hydrogen in treating patients with COVID-19, which may offer a prospective solution to adjuvant therapy for COVID-19 Patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Journal of clinical biochemistry and nutrition - 73(2023), 3 vom: 23. Nov., Seite 228-233 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shi, Meng-Meng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical trial |
|---|
| Anmerkungen: |
Date Revised 17.11.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3164/jcbn.23-32 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364621362 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364621362 | ||
| 003 | DE-627 | ||
| 005 | 20231226095819.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3164/jcbn.23-32 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1215.xml |
| 035 | |a (DE-627)NLM364621362 | ||
| 035 | |a (NLM)37970554 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shi, Meng-Meng |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The efficacy of hydrogen/oxygen therapy favored the recovery of omicron SARS-CoV-2 variant infection |b results of a multicenter, randomized, controlled trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023 JCBN. | ||
| 520 | |a Clinical studies had found that hydrogen/oxygen mixed inhalation was beneficial to ameliorate the respiratory symptoms in the adjuvant treatment of patients with COVID-19. We aimed to explore the efficacy of hydrogen/oxygen therapy in favoring the recovery of Omicron SARS-CoV-2 variant infection. There were 64 patients who randomly assigned to receive hydrogen/oxygen inhalation (32 patients) and oxygen inhalation (32 patients). The average shedding duration of Omicron in hydrogen/oxygen group was shorter than oxygen group. The trend of cumulative negative conversion rate of Omicron increased gradually after the third day. The IL-6 levels in hydrogen/oxygen group decreased by 22.8% compared with the baseline. After hydrogen/oxygen mixed gas inhalation, the lymphocyte count increased to 61.1% of the baseline on the 3rd day in the hydrogen/oxygen group. More patients in the hydrogen/oxygen group had resolution of pulmonary lesions. Our study showed the beneficial trends of molecular hydrogen in treating patients with COVID-19, which may offer a prospective solution to adjuvant therapy for COVID-19 Patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Omicron variant | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a hydrogen/oxygen therapy | |
| 700 | 1 | |a Chen, Yun-Tian |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiao-Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yun-Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Bao, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Wei-Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Yuan-Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Qing-Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Qu, Jie-Ming |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical biochemistry and nutrition |d 1993 |g 73(2023), 3 vom: 23. Nov., Seite 228-233 |w (DE-627)NLM086732099 |x 0912-0009 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2023 |g number:3 |g day:23 |g month:11 |g pages:228-233 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3164/jcbn.23-32 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2023 |e 3 |b 23 |c 11 |h 228-233 | ||